You could imagine that big pharma will fight tooth and nail not to have the patents extended. However, I do believe that there are significant grounds for the core patents to be extended.
In the meantime, if ddRNAi ends up being the giant breakthrough in modern medicine (as some of us on this board fundamentally believe), I can't imagine Big Pharma would want to wait on the sidelines until 2018 before they start R&D of their own.
Even if the 2018 patents are not extended, revenue could/should be realized residually if the commercial license agreements are structured accordingly. For example, a certain % of revenue ongoing for any products developed leveraging the innovations covered by the Graham patents (even beyond the 2018 date). Benetic has the leverage potentially to strike these deals, because the risk of big pharma not doing so could be greater than giving away a small % of potential gains.
Who knows really... but it is certainly fun (and so far profitable) to watch this play out.
cashed up, ready to make medical history, page-35
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)